Does the media favor XENE or INCY?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Incyte. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 12 mentions for Incyte. Incyte's average media sentiment score of 0.94 beat Xenon Pharmaceuticals' score of 0.65 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or XENE?

In the previous week, BioNTech had 9 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 24 mentions for BioNTech and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat BioNTech's score of -0.11 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or XENE?

In the previous week, United Therapeutics had 18 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 33 mentions for United Therapeutics and 15 mentions for Xenon Pharmaceuticals. United Therapeutics' average media sentiment score of 0.68 beat Xenon Pharmaceuticals' score of 0.65 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRNA or XENE?

In the previous week, Moderna had 41 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 56 mentions for Moderna and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Moderna's score of 0.49 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 21 Very Positive mention(s) 8 Positive mention(s) 15 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or INSM?

In the previous week, Insmed had 8 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 23 mentions for Insmed and 15 mentions for Xenon Pharmaceuticals. Insmed's average media sentiment score of 0.70 beat Xenon Pharmaceuticals' score of 0.65 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Xenon Pharmaceuticals (XENE) Competitors

$63.36 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$63.73 +0.37 (+0.58%)

As of 07:24 AM Eastern

Compare

XENE vs. INCY, BNTX, UTHR, MRNA, and INSM

Should you buy Xenon Pharmaceuticals stock or one of its competitors? MarketBeat compares Xenon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenon Pharmaceuticals include Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), Moderna (MRNA), and Insmed (INSM). These companies are all part of the "biotechnology" industry.

How does Xenon Pharmaceuticals compare to Incyte?

Xenon Pharmaceuticals (NASDAQ:XENE) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Incyte has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A
Incyte	$5.14B	4.75	$1.29B	$7.85	15.36

Incyte has a net margin of 27.71% compared to Xenon Pharmaceuticals' net margin of 0.00%. Incyte's return on equity of 29.93% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Incyte	27.71%	29.93%	22.88%

Xenon Pharmaceuticals currently has a consensus target price of $77.13, suggesting a potential upside of 21.74%. Incyte has a consensus target price of $120.40, suggesting a potential downside of 0.13%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xenon Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Incyte. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 12 mentions for Incyte. Incyte's average media sentiment score of 0.94 beat Xenon Pharmaceuticals' score of 0.65 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats Xenon Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Xenon Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A

In the previous week, BioNTech had 9 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 24 mentions for BioNTech and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat BioNTech's score of -0.11 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

15.5% of BioNTech shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioNTech currently has a consensus price target of $127.81, suggesting a potential upside of 36.45%. Xenon Pharmaceuticals has a consensus price target of $77.13, suggesting a potential upside of 21.74%. Given BioNTech's higher possible upside, equities analysts plainly believe BioNTech is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

United Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.26	$1.33B	$27.95	19.28
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A

In the previous week, United Therapeutics had 18 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 33 mentions for United Therapeutics and 15 mentions for Xenon Pharmaceuticals. United Therapeutics' average media sentiment score of 0.68 beat Xenon Pharmaceuticals' score of 0.65 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Xenon Pharmaceuticals' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

United Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

United Therapeutics currently has a consensus price target of $646.00, indicating a potential upside of 19.89%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

United Therapeutics beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Xenon Pharmaceuticals has lower revenue, but higher earnings than Moderna. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.15	-$2.82B	-$7.99	N/A
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A

In the previous week, Moderna had 41 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 56 mentions for Moderna and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Moderna's score of 0.49 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	21 Very Positive mention(s)	8 Positive mention(s)	15 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Moderna presently has a consensus price target of $42.13, indicating a potential downside of 28.79%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Summary

Xenon Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Insmed?

Xenon Pharmaceuticals (NASDAQ:XENE) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Xenon Pharmaceuticals presently has a consensus price target of $77.13, suggesting a potential upside of 21.74%. Insmed has a consensus price target of $205.26, suggesting a potential upside of 56.57%. Given Insmed's higher possible upside, analysts clearly believe Insmed is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Insmed had 8 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 23 mentions for Insmed and 15 mentions for Xenon Pharmaceuticals. Insmed's average media sentiment score of 0.70 beat Xenon Pharmaceuticals' score of 0.65 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	816.67	-$345.91M	-$4.74	N/A
Insmed	$1.14B	24.98	-$1.28B	-$4.11	N/A

Xenon Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Xenon Pharmaceuticals' return on equity of -43.98% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Xenon Pharmaceuticals beats Insmed on 8 of the 15 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.13B	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-13.37	9.02	270.61	25.05
Price / Sales	816.67	1,287.31	657.91	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	8.41	17.69	11.26	6.43
Net Income	-$345.91M	-$13.25M	$3.45B	$348.10M
7 Day Performance	1.77%	5.04%	3.41%	2.66%
1 Month Performance	-8.07%	-2.10%	-0.71%	-0.85%
1 Year Performance	89.53%	61.50%	77.43%	23.96%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	2.5807 of 5 stars	$63.36 flat	$77.13 +21.7%	+89.5%	$6.13B	$7.50M	N/A	210	Trending News Earnings Report Analyst Forecast Analyst Revision
INCY Incyte	3.4043 of 5 stars	$118.43 -0.9%	$119.60 +1.0%	+53.8%	$24.23B	$5.14B	15.09	2,844
BNTX BioNTech	3.8565 of 5 stars	$92.25 +1.8%	$129.13 +40.0%	-16.1%	$22.91B	$3.25B	N/A	7,807	Analyst Downgrade
UTHR United Therapeutics	4.4315 of 5 stars	$516.31 -0.3%	$648.33 +25.6%	+78.7%	$21.98B	$3.18B	19.06	1,400	Trending News Earnings Report
MRNA Moderna	1.3628 of 5 stars	$55.14 +0.6%	$42.13 -23.6%	+126.5%	$21.75B	$1.94B	N/A	4,700	Trending News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. INCY, BNTX, UTHR, MRNA, and INSM

How does Xenon Pharmaceuticals compare to Incyte?

Summary

How does Xenon Pharmaceuticals compare to BioNTech?

Summary

How does Xenon Pharmaceuticals compare to United Therapeutics?

Summary

How does Xenon Pharmaceuticals compare to Moderna?

Summary

How does Xenon Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. INCY, BNTX, UTHR, MRNA, and INSM

How does Xenon Pharmaceuticals compare to Incyte?

Which has higher valuation and earnings, XENE or INCY?

Is XENE or INCY more profitable?

Do analysts recommend XENE or INCY?

Do institutionals & insiders have more ownership in XENE or INCY?

Which has more volatility and risk, XENE or INCY?

Does the media favor XENE or INCY?

Summary

How does Xenon Pharmaceuticals compare to BioNTech?

Which has preferable earnings and valuation, BNTX or XENE?

Does the media prefer BNTX or XENE?

Which has more volatility and risk, BNTX or XENE?

Is BNTX or XENE more profitable?

Do institutionals and insiders have more ownership in BNTX or XENE?

Do analysts rate BNTX or XENE?

Summary

How does Xenon Pharmaceuticals compare to United Therapeutics?

Which has higher valuation & earnings, UTHR or XENE?

Does the media prefer UTHR or XENE?

Is UTHR or XENE more profitable?

Which has more risk and volatility, UTHR or XENE?

Do analysts prefer UTHR or XENE?

Do institutionals & insiders hold more shares of UTHR or XENE?

Summary

How does Xenon Pharmaceuticals compare to Moderna?

Which has better valuation and earnings, MRNA or XENE?

Does the media refer more to MRNA or XENE?

Do insiders & institutionals believe in MRNA or XENE?

Which has more volatility and risk, MRNA or XENE?

Do analysts prefer MRNA or XENE?

Is MRNA or XENE more profitable?

Summary

How does Xenon Pharmaceuticals compare to Insmed?

Do analysts recommend XENE or INSM?

Does the media favor XENE or INSM?

Which has more volatility and risk, XENE or INSM?

Do insiders and institutionals have more ownership in XENE or INSM?

Which has better valuation & earnings, XENE or INSM?

Is XENE or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools